|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Characteristics | Healthy controls(*n* = 48) | Infection controls(*n* = 42) | All sepsis patients(*n* = 91) | Sepsis survivors patients(*n* = 75) | Sepsis non-survivors patients(*n* = 16) | *P* value(Survivors VS Non-survivors) |
| Male/Female | 28/20 | 32/10 | 48/43 | 38/37 | 10/6 | 0.0812 |
| Age, years | 51(35-61) | 65(56-78) | 59(47-70) | 62(47-72) | 60(51-67) | 0.7040 |
| WBC, 109/L | NA | 11.3(7.7-13.8) | 11.9(6.0-14.4) | 14.5(6.9-17.2) | 11.5(6.2-15.8) | 0.2590 |
| PLT, 109/L | NA | 190(113-256) | 158(80-254) | 118(81-248) | 159(54-255) | 0.9472 |
| CRP, mg/L | NA | 48(11-75) | 101(34-180) | 88(30-156) | 113(55-189) | 0.1275 |
| PCT, ng/mL | NA | 17.1(0.4-24.8) | 38.9(1.9-49.5) | 31.4(0.5-59.4) | 70.1(3.6-105.1) | 0.2348 |
| Infection site, no. of patients |
| Respiratory | NA | 42 | 40 | 26 | 14 | - |
| Abdominal | NA | 0 | 5 | 4 | 1 | - |
| Vascular | NA | 0 | 24 | 22 | 2 | - |
| Urinary | NA | 0 | 18 | 16 | 2 | - |
| Other | NA | 0 | 21 | 17 | 4 | - |
| Isolates, no. of patients |
| Gram positive | NA | 12 | 26 | 22 | 4 | - |
| Gram negative | NA | 24 | 42 | 36 | 6 | - |
| Fungus | NA | 2 | 6 | 4 | 2 | - |
| Miscellaneous | NA | 2 | 10 | 6 | 4 | - |
| Other | NA | 2 | 7 | 7 | 0 | - |
| Sepsis shock | NA | - | 26 | 16 | 10 | **0.0103** |
| SOFA score | NA | - | 6(4-8) | 8(4-8) | 9(8-10) | **<0.0001** |
| ICU stay | NA | 10(8-13) | 27(10-48) | 25(10-48) | 19(9-26) | 0.2511 |

**Supplemental Table 1. Clinical characteristics of sepsis patients and healthy volunteers in adult discovery cohort.**

Categorical variables are expressed as *n* (%), and continuous variables were expressed as median (interquartile range). Comparisons between sepsis patients and sepsis shock patients, survivors and non-survivors were performed with chi-square or Fisher exact tests for qualitative variables and Mann-Whitney *U* for quantitative variables. SOFA score was measured after 24 hours of ICU stay.

**Abbreviations:** WBC, white blood cell; PLT, platelet; CRP, C-reactive protein; PCT, procalcitonin; SOFA, Sequential Organ Failure Assessment; ICU, intensive care unit; NA, not applicable.

**Supplemental Table 2. Clinical characteristics of sepsis patients and healthy volunteers in the adult validation cohort.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Characteristics | Healthy controls(*n* = 92) | Infection controls(*n* = 116) | All sepsis patients(*n* = 163) | Sepsis survivors patients(*n* = 102) | Sepsis non-survivors patients(*n* = 61) | *P* value(Survivors VS Non-survivors) |
| Male/Female | 49/43 | 73/43 | 86/77 | 56/46 | 30/31 | 0.479 |
| Age, years | 53(50-60) | 65(59-79) | 56(53-76) | 65(55-79) | 64(56-73) | 0.522 |
| WBC, 109/L | NA | 10.7(6.3-13.8) | 12.0(6.3-13.9) | 11.1(6.5-12.7) | 10.0(8.3-12.1) | 0.417 |
| CRP, mg/L | NA | 43.5(5.0-69.2) | 138(73.6-200.0) | 127.2(68-200.0) | 146.4(109.3-200.0) | 0.104 |
| PCT, ng/mL | NA | 9.9(0.1-9.1) | 39.6(2.8-54.7) | 51.4(2.7-56.6) | 62.4(4.9-98.1) | 0.190 |
| PLT, 109/L | NA | 223(177-278) | 120(60-165) | 133(73-207) | 95(43-144) | 0.200 |
| Infection site, no. of patients |
| Respiratory | NA | 85 | 67 | 45 | 22 | - |
| Abdominal | NA | 9 | 45 | 28 | 17 | - |
| Vascular | NA | 0 | 19 | 6 | 13 | - |
| Urinary | NA | 6 | 14 | 10 | 4 | - |
| Other | NA | 16 | 18 | 13 | 5 | - |
| Isolates, no. of patients |
| Gram positive | NA | 36 | 47 | 32 | 15 | - |
| Gram negative | NA | 52 | 67 | 44 | 23 | - |
| Fungus | NA | 9 | 15 | 9 | 6 | - |
| Miscellaneous | NA | 12 | 28 | 12 | 16 | - |
| Other | NA | 7 | 6 | 5 | 1 | - |
| Sepsis shock | NA | - | 61 | 30 | 31 | **0.0001** |
| APACHE Ⅱ score | NA | 8(4-12) | 18(13-23) | 14(9-18) | 21(17-27) | **0.0025** |
| SOFA score | NA | - | 8(5-11) | 7(4-9) | 11(9-13) | **0.0014** |
| ICU stay | NA | 12(5-19) | 10(3-15) | 11(3-15) | 8(1-11) | 0.469 |

Categorical variables are expressed as *n* (%), and continuous variables were expressed as median (interquartile range). Comparisons between sepsis patients and sepsis shock patients, survivors and non-survivors were performed with chi-square or Fisher exact tests for qualitative variables and Mann-Whitney *U* for quantitative variables. APACHE Ⅱ score and SOFA score were measured after 24 hours of ICU stay.

**Abbreviations:** WBC, white blood cell; PLT, platelet; CRP, C-reactive protein; PCT, procalcitonin; APACHE II, acute physiology and chronic health evaluation II; SOFA, Sequential Organ Failure Assessment; ICU, intensive care unit; NA, not applicable.

**Supplemental Table 3. Clinical characteristics of sepsis patients and healthy volunteers in the pediatric discovery cohort.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Characteristics | Healthy controls(*n* = 53) | All sepsis patients(*n* = 61) | Sepsis survivors patients(*n* = 50) | Sepsis non-survivors patients(*n* = 11) | *P* value(Survivors VS Non-survivors) |
| Male/Female | 30/23 | 30/31 | 23/27 | 7/4 | 0.280 |
| Age, years | 7(3-12) | 3(1-4) | 3(2-8) | 2(1-3) | 0.222 |
| WBC, 109/L | NA | 15.1(10.2-21.3) | 14.5(10.6-18.4) | 12.3(5.8-18.8) | 0.204 |
| CRP, mg/L | NA | 76.7(21.9-128.4) | 62.2(17.0-101.0) | 98.8(31.0-179.4) | 0.199 |
| PCT, ng/mL | NA | 7.1(0.3-3.7) | 1.2(0.3-1.5) | 30.3(3.2-49.7) | **<0.0001** |
| Infection site, no. of patients |
| Respiratory | NA | 47 | 40 | 7 | - |
| Abdominal | NA | 3 | 2 | 1 | - |
| Vascular | NA | 7 | 4 | 3 | - |
| Urinary | NA | 3 | 2 | 1 | - |
| Other | NA | 4 | 3 | 1 | - |
| Isolates, no. of patients |
| Gram positive | NA | 15 | 13 | 2 | - |
| Gram negative | NA | 6 | 4 | 2 | - |
| Virus | NA | 29 | 24 | 5 | - |
| Fungus | NA | 2 | 2 | 0 | - |
| Miscellaneous | NA | 6 | 4 | 2 | - |
| Other | NA | 3 | 3 | 0 | - |
| Sepsis shock | NA | 12 | 4 | 8 | **<0.0001** |
| pSOFA socre | NA | 5(4-8) | 5(2-6) | 8(7-9) | **0.0002** |
| ICU stay | NA | 7(5-8) | 7(5-8) | 9(2-8) | 0.252 |

Categorical variables are expressed as *n* (%), and continuous variables were expressed as median (interquartile range). Comparisons between sepsis patients and sepsis shock patients, survivors and non-survivors were performed with chi-square or Fisher exact tests for qualitative variables and Mann-Whitney *U* for quantitative variables. pSOFA score was measured after 24 hours of ICU stay.

**Abbreviations:** WBC, white blood cell; CRP, C-reactive protein; PCT, procalcitonin; pSOFA, pediatric Sequential Organ Failure Assessment; ICU, intensive care unit; NA, not applicable.

**Supplemental Table 4. Clinical characteristics of sepsis patients and healthy volunteers in the pediatric validation cohort.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Characteristics | Healthy controls(*n* = 98) | Infection controls(*n* = 102) | All sepsis patients(*n* = 145) | Sepsis survivors patients(*n* = 105) | Sepsis non-survivors patients(*n* = 40) | *P* value(Survivors VS Nonsurvivors) |
| Male/Female | 52/46 | 57/45 | 79/64 | 57/48 | 24/16 | 0.476 |
| Age, years | 8(6-12) | 5(2-8) | 7(4-10) | 6(3-8) | 7(3-11) | 0.690 |
| WBC, 109/L | NA | 10.4(6.5-12.2) | 14.1(5.6-19.5) | 15.8(5.9-20.4) | 9.2(5.5-10.5) | 0.103 |
| CRP, mg/L | NA | 19.0(1.8-30.4) | 50.0(4.5-70.1) | 45.7(4.2-68.7) | 67.9(4.8-126.5) | 0.055 |
| PCT, ng/mL | NA | 0.5(0.1-0.4) | 14.3(0.7-16.2) | 11.0(0.6-11.0) | 28.4(2.4-40.0) | **0.0003** |
| Infection site, no. of patients |
| Respiratory | NA | 82 | 69 | 44 | 27 | - |
| Abdominal | NA | 10 | 30 | 18 | 12 | - |
| Vascular | NA | 0 | 14 | 8 | 6 | - |
| Urinary | NA | 6 | 23 | 14 | 9 | - |
| Other | NA | 9 | 31 | 21 | 10 | - |
| Isolates, no. of patients |
| Gram positive | NA | 17 | 33 | 23 | 10 | - |
| Gram negative | NA | 26 | 28 | 20 | 8 | - |
| Virus | NA | 49 | 60 | 45 | 15 | - |
| Fungus | NA | 0 | 7 | 5 | 2 | - |
| Miscellaneous | NA | 7 | 10 | 6 | 4 | - |
| Other | NA | 3 | 5 | 6 | 1 | - |
| Sepsis shock | NA | - | 44 | 23 | 21 | **<0.0001** |
| pSOFA score | NA | 0.07(0-1) | 7(4-10) | 6(3-7) | 12(7-15) | **0.0001** |
| ICU stay | NA | 5(4-7) | 13(7-15) | 15(8-17) | 8(4-12) | 0.294 |

Categorical variables are expressed as *n* (%), and continuous variables were expressed as median (interquartile range). Comparisons between sepsis patients and sepsis shock patients, survivors and non-survivors were performed with chi-square or Fisher exact tests for qualitative variables and Mann-Whitney *U* for quantitative variables. pSOFA score was measured after 24 hours of ICU stay.

**Abbreviations:** WBC, white blood cell; CRP, C-reactive protein; PCT, procalcitonin; pSOFA, pediatric Sequential Organ Failure Assessment; ICU, intensive care unit; NA, not applicable.

**Supplemental Table 5. Association between admission concentrations of serum IGFBP6 and 28-day mortality for the discovery cohort of adults with sepsis.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Parameters | Standard error | Wald | IQR Hazard Ratio (95% CI) | *P* value |
| Univariate Cox models |
| IGFBP6 | 0.003 | 16.884 | 1.011 (1.006 – 1.016) | **<0.001** |
| SOFA | 0.098 | 16.339 | 1.487 (1.227 – 1.803) | **<0.001** |
| CRP | 0.004 | 5.321 | 1.009 (1.001 – 1.016) | **0.021** |
| PCT | 0.002 | 1.583 | 1.003 (0.998 – 1.007) | 0.208 |
| WBC | 0.037 | 0.329 | 0.979 (0.911 – 1.052) | 0.566 |
| Neu | 0.041 | 0.863 | 0.962 (0.888 – 1.043) | 0.353 |
| PLT | 0.002 | 0.163 | 1.001 (0.997 – 1.005) | 0.687 |
| Cr | 0.001 | 7.906 | 1.004(1.001 – 1.006) | **0.005** |
| Multivariate Cox models |
| IGFBP6 | 0.003 | 5.258 | 1.008 (1.001 – 1.015) | **0.022** |
| SOFA | 0.196 | 4.076 | 1.485 (1.012 – 2.181) | **0.043** |
| CRP | 0.005 | 3.804 | 1.011 (1.000 – 1.022) | 0.051 |
| PCT | 0.004 | 1.934 | 0.995 (0.988 – 1.002) | 0.164 |
| WBC | 0.158 | 0.312 | 0.915 (0.671 – 1.248) | 0.577 |
| Neu | 0.168 | 0.052 | 0.963 (0.693 – 1.337) | 0.820 |
| PLT | 0.003 | 0.144 | 0.999 (0.994 – 1.004) | 0.705 |
| Cr | 0.002 | 2.521 | 1.003 (0.999 – 1.008) | 0.112 |

Boldface value indicate significance at *P*<0.05. IQR, interquartile range; CI, confidence interval.

**Supplemental Table 6. Association between admission concentrations of serum IGFBP6 and 28-day mortality in the validation cohort of adults with sepsis.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Parameters | Standard error | Wald | IQR Hazard Ratio (95% CI) | *P* value |
| Univariate Cox models |
| IGFBP6 | 0.002 | 45.865 | 1.011 (1.008 – 1.015) | **<0.0001** |
| SOFA | 0.035 | 33.869 | 1.229 (1.146 – 1.317) | **<0.0001** |
| APACHE Ⅱ | 0.014 | 26.627 | 1.075 (1.046 – 1.105) | **<0.0001** |
| WBC | 0.021 | 0.517 | 1.016 (0.974 – 1.059) | 0.472 |
| CRP | 0.002 | 4.654 | 1.004 (1.000 – 1.007) | **0.031** |
| PCT | 0.005 | 2.849 | 1.009 (0.999 – 1.019) | 0.091 |
| Neu | 0.010 | 0.960 | 1.010 (0.991 – 1.029) | 0.327 |
| Multivariate Cox models |
| IGFBP6 | 0.002 | 17.8 | 1.010 (1.006 – 1.015) | **<0.0001** |
| SOFA | 0.045 | 7.871 | 1.146 (1.050 – 1.252) | **0.002** |
| APACHE Ⅱ | 0.021 | 0.971 | 1.021 (0.980 – 1.064) | 0.324 |
| WBC | 0.021 | 0.653 | 1.107 (0.975 – 1.060) | 0.441 |
| CRP | 0.002 | 0.182 | 0.999 (0.995 – 1.003) | 0.564 |
| PCT | 0.006 | 0.011 | 1.001 (0.989 – 1.013) | 0.336 |
| Neu | 0.010 | 0.547 | 0.992 (0.972 – 1.011) | 0.392 |

Boldface value indicate significance at *P*<0.05. IQR, interquartile range; CI, confidence interval.

**Supplemental Table 7. Correlation coefficient of ROC curve for predicting sepsis death in the adult discovery cohort.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Parameter | Cutoff value | AUC (95% CI) | Sensitivity (%) | Specificity (%) | Youden index (%) | *P* value |
| IGFBP6 | 221.1 | 0.89 (0.82 – 0.96) | 87.50 | 82.67 | 70.17 | **<0.0001** |
| SOFA | 7.50 | 0.89 (0.82 – 0.96) | 87.50 | 78.67 | 66.17 | **<0.0001** |
| CRP | 121.7 | 0.68 (0.55 – 0.81) | 68.75 | 63.38 | 32.13 | **0.0273** |
| PCT | 20.49 | 0.69 (0.54 – 0.83) | 73.33 | 64.71 | 38.04 | **0.0224** |
| WBC | 8.710 | 0.57 (0.39 – 0.76) | 58.33 | 67.74 | 26.07 | 0.4284 |
| PLT | 190.0 | 0.55 (0.36 – 0.75) | 50.00 | 72.88 | 22.88 | 0.5702 |

Boldface value indicate significance at *P*<0.05.

**Supplemental Table 8. Correlation coefficient of ROC curve to predict death with sepsis in the adult validation cohort.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Parameter | Cutoff value | AUC (95% CI) | Sensitivity (%) | Specificity (%) | Youden index (%) | *P* value |
| IGFBP6 | 209.7 | 0.76 (0.69 – 0.83) | 77.05 | 71.57 | 48.62 | **<0.0001** |
| SOFA | 5.50 | 0.75 (0.67 – 0.82) | 93.44 | 41.18 | 34.62 | **<0.0001** |
| APACHE Ⅱ | 17.50 | 0.68 (0.60 – 0.77) | 72.13 | 58.82 | 30.95 | **0.0001** |
| CRP | 28.53 | 0.59 (0.51 – 0.68) | 90.16 | 29.41 | 19.57 | **0.0465** |
| PCT | 15.31 | 0.65 (0.56 – 0.76) | 56.67 | 75.49 | 32.16 | **0.0019** |
| WBC | 21.36 | 0.50 (0.41 – 0.59) | 13.11 | 95.10 | 8.21 | 0.9891 |

Boldface value indicate significance at *P*<0.05.

**Supplemental Table 9. Association between admission concentrations of serum IGFBP6 and 28-day mortality of septic patients in the pediatric discovery cohort.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Parameters | Standard error | Wald | IQR Hazard Ratio (95% CI) | *P* value |
| Univariate Cox models |
| IGFBP6 | 0.003 | 16.403 | 1.011 (1.006 – 1.016) | **<0.001** |
| pSOFA | 0.123 | 6.631 | 1.374 (1.079 – 1.750) | **0.010** |
| WBC | 0.047 | 1.659 | 0.941 (0.859 – 1.032) | 0.198 |
| PCT | 0.013 | 13.028 | 1.049 (1.022 – 1.077) | **<0.001** |
| CRP | 0.005 | 0.028 | 1.001 (0.992 – 1.010) | 0.868 |
| Neu | 0.054 | 0.494 | 0.963 (0.866 – 1.070) | 0.482 |
| PLT | 0.002 | 6.534 | 0.994 (0.990 – 0.999) | **0.011** |
| Multivariate Cox models |
| IGFBP6 | 0.008 | 4.817 | 1.018 (1.002 – 1.035) | **0.028** |
| pSOFA | 0.243 | 2.628 | 1.484 (0.921 – 2.391) | 0.105 |
| WBC | 0.311 | 1.058 | 0.726 (0.395 – 1.336) | 0.304 |
| PCT | 0.028 | 1.210 | 0.990 (0.979 – 1.002) | 0.102 |
| CRP | 0.006 | 2.670 | 1.081 (0.967 – 1.096) | 0.216 |
| Neu | 0.363 | 0.881 | 1.406 (0.690 – 2.862) | 0.348 |
| PLT | 0.003 | 1.014 | 0.997 (0.991 – 1.003) | 0.314 |

Boldface value indicate significance at *P*<0.05. IQR, interquartile range; CI, confidence interval.

**Supplemental Table 10. Association between admission concentrations of serum IGFBP6 and 28-day mortality of sepsis patients in the pediatric validation cohort.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Parameters | Standard error | Wald | IQR Hazard Ratio (95% CI) | *P* value |
| Univariate Cox models |
| IGFBP6 | 0.002 | 52.990 | 1.014 (1.010 – 1.018) | **<0.001** |
| pSOFA | 0.037 | 56.516 | 1.323 (1.230 – 1.423) | **<0.001** |
| PCT | 0.002 | 52.756 | 1.016 (1.012 – 1.020) | **<0.001** |
| CRP | 0.003 | 3.338 | 1.006 (1.000 – 1.012) | **0.068** |
| Neu | 0.025 | 1.655 | 0.969 (0.923 – 1.017) | 0.198 |
| Multivariate Cox models |
| IGFBP6 | 0.007 | 4.727 | 1.007 (1.001 – 1.013) | **0.030** |
| pSOFA | 0.061 | 8.612 | 1.194 (1.061 – 1.345) | **0.003** |
| PCT | 0.004 | 0.332 | 1.002 (0.994 – 1.011) | 0.564 |
| CRP | 0.004 | 0.590 | 0.997 (0.989 – 1.005) | 0.442 |
| Neu | 0.030 | 0.843 | 0.972 (0.916 – 1.032) | 0.358 |

Boldface value indicate significance at *P*<0.05. IQR, interquartile range; CI, confidence interval.

**Supplemental Table 11. Correlation coefficient of ROC curve for predicting sepsis death in the pediatric discovery cohort.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Parameter | Cutoff value | AUC (95% CI) | Sensitivity (%) | Specificity (%) | Youden index (%) | *P* value |
| IGFBP6 | 242.4 | 0.88 (0.75 – 1.00) | 72.73 | 100 | 72.73 | **<0.0001** |
| pSOFA | 6.500 | 0.82 (0.69 – 0.94) | 81.82 | 78.00 | 59.82 | **0.0008** |
| CRP | 178.1 | 0.58 (0.38 – 0.79) | 27.27 | 95.92 | 23.19 | 0.3900 |
| PCT | 1.440 | 0.68 (0.48 – 0.89) | 72.73 | 71.74 | 44.47 | 0.0587 |
| WBC | 10.34 | 0.61 (0.42 – 0.81) | 45.45 | 79.59 | 25.04 | 0.2478 |
| PLT | 255.0 | 0.83 (0.66 – 0.99) | 81.82 | 87.76 | 69.58 | **0.0007** |

Boldface value indicate significance at *P*<0.05.

**Supplemental Table 12. Correlation coefficient of ROC curve for predicting sepsis death in the pediatric validation cohort.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Parameter | Cutoff value | AUC (95% CI) | Sensitivity (%) | Specificity (%) | Youden index (%) | *P* value |
| IGFBP6 | 165.7 | 0.83 (0.75 – 0.90) | 62.50 | 88.57 | 51.07 | **<0.0001** |
| pSOFA | 9.500 | 0.79 (0.71 – 0.88) | 67.50 | 86.67 | 54.17 | **<0.0001** |
| CRP | 118.5 | 0.57 (0.46 – 0.68) | 25.00 | 94.29 | 19.29 | 0.1751 |
| PCT | 1.905 | 0.72 (0.63 – 0.81) | 82.50 | 50.48 | 32.98 | **<0.0001** |
| WBC | 8.815 | 0.65 (0.54 – 0.75) | 60.00 | 69.52 | 29.52 | **0.0067** |
| PLT | 75.50 | 0.60 (0.49 – 0.72) | 35.00 | 91.43 | 26.43 | 0.0610 |

Boldface value indicate significance at *P*<0.05.

**Supplemental Table 13. The primer sequence of the CCL2 promoter.**

|  |  |  |
| --- | --- | --- |
| Primer Name | Sequence (5’to 3’) | Modification |
| CCL2-F | AAGAAATCTAAACCTGGAAAGCTGAATTAA |  |
| CCL2-R | TTAATTCAGCTTTCCAGGTTTAGATTTCTT |  |
| CCL2-F-BIO | AAGAAATCTAAACCTGGAAAGCTGAATTAA | 5’BIO |
| mtCCL2-F | AAGAAATCTAAACGACGAAAGCTGAATTAA |  |
| mtCCL2-R | TTAATTCAGCTTTCGTCGTTTAGATTTCTT |  |
| mtCCL2-F-BIO | AAGAAATCTAAACGACGAAAGCTGAATTAA | 5’BIO |

Note: F, forward primer; R, reverse prime

**Supplemental Table 14. siRNA sequences used to target PHB2 gene.**

|  |  |  |
| --- | --- | --- |
| Name | Forward 5’- 3’ | Reverse 5’- 3’ |
| siNC | UUCUCCGAACGUGUCACGUTT | ACGUGACACGUUCGGAGAATT |
| siPHB2-1 (PHB2-mus-942) | CCACAUCACAGAACCGAAUTT | AUUCGGUUCUGUGAUGUGGTT |
| siPHB2-2 (PHB2-mus-544) | GCUGCCGUCCAUUGUUAAUTT | AUUAACAAUGGACGGCAGCTT |
| siPHB2-3 (PHB2-mus-887) | GGCUAUAUCAAGCUCCGAATT | UUCGGAGCUUGAUAUAGCCTT |

Note: siPHB2, small interfering PHB2